Xylazine HCl is a strong α2-adrenergic receptor agonist, mainly used as a sedative, muscle relaxant and analgesic agent in anesthesia of different species [1]. It is well known that α2-adrenoceptor agonists inhibit the sympathetic outflow in the central nervous system via their actions on α2-adrenoceptors. In addition, the α2-agonists also inhibit the insulin release through their actions on α2-adrenoceptors in the pancreas β-cells [2].
In vitro: NA
In vivo: Xylazine HCl showed analgesic activity at a dose rate of 30 mg/kg intraperitoneally [1]. Xylazine HCl (1, 2, 4, and 8 mg/kg, intramuscularly) also dose-dependently decreased epinephrine, plasma catecholamine and cortisol levels, inhibited insulin release and lipolysis, and increased plasma
In vitro: NA
In vivo: Xylazine HCl showed analgesic activity at a dose rate of 30 mg/kg intraperitoneally [1]. Xylazine HCl (1, 2, 4, and 8 mg/kg, intramuscularly) also dose-dependently decreased epinephrine, plasma catecholamine and cortisol levels, inhibited insulin release and lipolysis, and increased plasma